Damora Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 State St Ste 100, Boston, Massachuset...Phone Number
(781) 281-9020Website
www.damoratx.comRevenue
$9.1 MillionStock Symbol
DMRAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Damora Therapeutics
Damora Therapeutics is a Waltham, Massachusetts-based biotechnology company focused on developing a new generation of disease-modifying subcutaneous biologics for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs). The company's pipeline targets two rare blood disorders Essential Thrombocythemia (ET), a chronic condition causing excess platelet production, and Myelofibrosis (MF), a blood cancer in which bone marrow is replaced by scar tissue for which no currently available treatments address the underlying genetic cause. Its lead program, DMR-001, is a potentially best-in-class monoclonal antibody specifically targeting mutCALR, with additional pipeline candidates DMR-002 and DMR-003 designed to address the broader spectrum of mutCALR MPN patients. The company's pipeline was developed from assets originated by Paragon Therapeutics, and its leadership team brings deep experience from Blueprint Medicines, Arcus Biosciences, Medivation, and other leadiRead more
Damora Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Damora Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Damora Therapeutics launches new products
Damora Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Damora Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Damora Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Damora Therapeutics
Earning: See what the market has to say on Damora Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Damora Therapeutics has new funding data
Check out if Damora Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Damora Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Damora Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Damora Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Damora Therapeutics.
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Compliance
Person-Based
Share Placement, Finance
New Hire
Executive Move
Executive Moves, New Hire
Damora Therapeutics News & Media
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) –Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential --Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment withDamora Announces Redomestication from Delaware to Cayman Islands
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company’s common stock automatically converted into one ordinary share, par value $0.00001 per share, of the
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Damora Therapeutics
Sign Up For FreeTo access detailed company insights
Damora Therapeutics is a Waltham, Massachusetts-based biotechnology company focused on developing a new generation of disease-modifying subcutaneous biologics for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs). The company's pipeline targets two rare blood disorders Essential Thrombocythemia (ET), a chronic c... Read More
